BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18382359)

  • 1. Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
    Baohua Y; Xiaoyan Z; Tiecheng Z; Tao Q; Daren S
    Diagn Mol Pathol; 2008 Sep; 17(3):159-65. PubMed ID: 18382359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
    Fenic I; Steger K; Gruber C; Arens C; Woenckhaus J
    Oncol Rep; 2007 Jul; 18(1):253-9. PubMed ID: 17549376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.
    Whyte DB; Holbeck SL
    Biochem Biophys Res Commun; 2006 Feb; 340(2):469-75. PubMed ID: 16376301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
    Riener MO; Bawohl M; Clavien PA; Jochum W
    Genes Chromosomes Cancer; 2008 May; 47(5):363-7. PubMed ID: 18181165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of AKT protein kinase activation on biologic behavior of diffuse large B cell lymphoma cells].
    Zhang TC; Zhou XY; Yu BH; Zhang TM; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2007 May; 36(5):318-23. PubMed ID: 17706139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C; Landthaler M; Vogt T
    Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIK3CA gene mutations in breast carcinoma in Malaysian patients.
    Ching-Shian Leong V; Jabal MF; Leong PP; Abdullah MA; Gul YA; Seow HF
    Cancer Genet Cytogenet; 2008 Dec; 187(2):74-9. PubMed ID: 19027487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
    Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
    Abubaker J; Bavi P; Al-Harbi S; Ibrahim M; Siraj AK; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    Oncogene; 2008 Jun; 27(25):3539-45. PubMed ID: 18193083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.
    Lin Y; Jiang X; Shen Y; Li M; Ma H; Xing M; Lu Y
    Endocr Relat Cancer; 2009 Mar; 16(1):301-10. PubMed ID: 18852163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations in glioblastoma multiforme.
    Hartmann C; Bartels G; Gehlhaar C; Holtkamp N; von Deimling A
    Acta Neuropathol; 2005 Jun; 109(6):639-42. PubMed ID: 15924253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
    Hollestelle A; Elstrodt F; Nagel JH; Kallemeijn WW; Schutte M
    Mol Cancer Res; 2007 Feb; 5(2):195-201. PubMed ID: 17314276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
    Gallia GL; Rand V; Siu IM; Eberhart CG; James CD; Marie SK; Oba-Shinjo SM; Carlotti CG; Caballero OL; Simpson AJ; Brock MV; Massion PP; Carson BS; Riggins GJ
    Mol Cancer Res; 2006 Oct; 4(10):709-14. PubMed ID: 17050665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
    Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
    Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.
    Tanaka Y; Kanai F; Tada M; Asaoka Y; Guleng B; Jazag A; Ohta M; Ikenoue T; Tateishi K; Obi S; Kawabe T; Yokosuka O; Omata M
    Oncogene; 2006 May; 25(20):2950-2. PubMed ID: 16331247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.
    Kastrup IB; Worm J; Ralfkiaer E; Hokland P; Guldberg P; Grønbaek K
    Eur J Haematol; 2008 Jan; 80(1):61-6. PubMed ID: 18028428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations in advanced ovarian carcinomas.
    Wang Y; Helland A; Holm R; Kristensen GB; Børresen-Dale AL
    Hum Mutat; 2005 Mar; 25(3):322. PubMed ID: 15712344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.
    Shibata T; Kokubu A; Tsuta K; Hirohashi S
    Cancer Lett; 2009 Oct; 283(2):203-11. PubMed ID: 19394761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.
    Cui W; Cai Y; Wang W; Liu Z; Wei P; Bi R; Chen W; Sun M; Zhou X
    J Transl Med; 2014 Jan; 12():10. PubMed ID: 24418330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.
    Hua K; Feng W; Cao Q; Zhou X; Lu X; Feng Y
    Int J Oncol; 2008 Nov; 33(5):959-67. PubMed ID: 18949358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.